Halozyme Therapeutics (HALO) stock soared 5% in pre-market trading on Wednesday, outperforming the broader markets. The surge was driven by the company's improved financial guidance for 2025 and the announcement of a new share repurchase program.

In a press release, Halozyme reiterated its 2024 financial guidance, indicating that its business performance last year met expectations. However, the company raised its 2025 financial guidance, projecting robust growth across key metrics:

• Total revenue is expected to grow 16-23% to $1.15-$1.23 billion, driven by increased royalty revenue and product sales.
• Adjusted EBITDA is projected to grow 24-32% to $755-$805 million, reflecting strong profitability.
• Non-GAAP diluted EPS is forecast to rise 21-30% to $4.95-$5.35, driven by top-line growth and operational efficiency.

Halozyme attributed the improved 2025 guidance to the strong performance of its products, including VYVGART, Darzalex SC, and Phesgo, as well as the recent launches of Ocrevus Zunovo, Tecentriq Hybreza, and Opdivo Qvantig. The company also announced a new $250 million accelerated share repurchase program, signaling its confidence in future growth prospects and commitment to enhancing shareholder value.